Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care
Kerem Kemal Soylemez, Emma Marie de Boo, Aysil Susuzlu, Joanne Lusher
Psychoactives September 2, 2025 DOI: 10.3390/psychoactives4030031 via OpenAlex
Summary
AI-generated from the abstractA narrative review of existing literature examines the potential of psychedelics such as psilocybin and LSD for treating dementia, a progressive neurodegenerative disease characterized by cognitive decline, memory loss, and behavioral changes. Psychedelics alter perception, mood, and cognition by affecting serotonin receptors and may promote neuroplasticity, reduce neuroinflammation, and enhance cognitive flexibility. These effects could slow disease progression and improve quality of life for patients, who often experience emotional distress, and may also help prevent dementia by fostering brain health. The review raises significant safety and ethical concerns and aims to critically raise awareness on the topic.
Study at a glance
| Characteristics | Narrative review Peer reviewed |
|---|---|
| Topics | Neuroplasticity |
| Keywords | Dementia Neuroscience Psychology Medicine |
| Citations | 2 |
| Key finding | Psychedelics may be a promising treatment for dementia by promoting neuroplasticity, reducing neuroinflammation, and enhancing cognitive flexibility, but significant safety and ethical concerns remain. |
Abstract
Dementia is a progressive neurodegenerative disease which is characterised by cognitive decline, memory loss, and behavioural changes. Patients suffering from dementia often experience emotional distress, sadness and depression which also impacts the wellbeing of their caregivers. Recent research has explored the potential of psychedelics, such as psilocybin and LSD, when treating various mental health conditions. Psychedelics are known to alter perception, mood and cognition by affecting serotonin receptors in the brain. Studies suggest that psychedelics may be a promising treatment for dementia patients and promote neuroplasticity, reduce neuroinflammation and enhance cognitive flexibility. These effects could potentially lead to a reduction in the progression of neurodegenerative diseases and improve the patients’ quality of life. Additionally, psychedelics might contribute to the prevention of dementia by fostering brain health and resilience against age-related decline. The application of psychedelics in dementia care might pose significant safety and ethical concerns. The present paper provides a narrative review of the existing literature on the use of psychedelics in treatment of dementia and its different types (Alzheimer’s) with the aim to raise awareness on the topic from a critical perspective.